Bicara Therapeutics shareholders elect three Class I directors, ratify KPMG

Bicara Therapeutics Inc.

Elected Kiran Mazumdar-Shaw, Jake Simson, and Ryan Cohlhepp as Class I directors for three-year terms.
Vote results: Mazumdar-Shaw 30.8M for, 14.4M withheld; Simson 37.6M for, 7.6M withheld; Cohlhepp 44.8M for, 0.4M withheld.
Broker non-votes of approximately 2.6M shares on each director election.
Ratification of KPMG as auditor for FY2025 passed with 47.7M for, 7.8K against, 3.3K abstain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.